$Moderna(MRNA.US) is now up more than 840% this yearShares jumped another 9% today to a fresh 2026 high near $278, up fr…
$Moderna(MRNA.US) is now up more than 840% this year
Shares jumped another 9% today to a fresh 2026 high near $278, up from $29.49 at the end of 2025That's more than 3x the 273% YTD gain of $Sandisk(SNDK.US), another one of the S&P 500's biggest winners of 2026Fuel for the runThe personalized cancer vaccine with $Merck(MRK.US) cut melanoma recurrence or death by 42% in a Phase 3 trial, with a 2027 launch targetedQ3 revenue came in at $1.31B vs $885M expected, and EPS was $0.38 vs an expected loss of $1.25Full-year revenue growth guidance was raised to 15% to 25%, from up to 10%, which would be the first year of growth since 2022Moderna went from a post-Covid cautionary tale to the hottest large-cap in the market in under a year, and it did it with drug data, not AI. With the stock at 9x its January price, every pipeline headline from here moves it hard in both directionsSource: StockMarket.News
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.